Pivot Pharmaceuticals (OTCQB:PVOTF) alongside its medical cannabis division announced an agreement with Solmic Research GmbH to acquire the worldwide rights to Solmic Solubilisation Technology for the development and commercialization of cannabinoid-containing natural extracts.
As quoted in the press release:
Solmic’s proprietary technology provides significantly higher bioavailability and stability compared to alternative oil-based formulations.
“Solmic is pleased to partner with Pivot’s experienced management team to develop water-soluble products containing cannabinoid natural extracts. Our proprietary technology will solve many issues that are faced by the fast-developing medical cannabis industry. By increasing bioavailability and stability, patients will be able to confidently take correct and accurate doses of oral solutions to help with their therapeutic needs,” states Solmic CEO Dr. Wolfgang Schoenfeld.